Vensica Medical Overview
Vensica is developing ViXe, a product that combines Xeomin, a commercial neurotoxin, and Vibe, a breakthrough, needle-free, ultrasound drug delivery device. Vibe is a breakthrough platform designed to deliver drugs directly into the bladder wall, providing uniform, controlled and localized treatments for urology applications. Vibe leverages a disruptive ultrasound technology to deliver drugs through the natural barriers of the urinary bladder. By generating cavitation bubbles, Vibe precisely microinjects the drugs into the bladder wall, ensuring a controlled and uniform delivery of medications and biologics.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
/PRNewswire/ -- Vensica Medical ("Vensica"), a pioneering urology therapeutics company, today announced the successful closing of an $11 million funding round....
Vensica Medical, a urology therapeutics company, has secured $11 million in funding to advance its needle-free delivery system for botulinum toxin A (Xeomin®) aimed at treating overactive bladder (OAB). The investment, led by Israel Biotech Fund with strategic partners Merz and Laborie, will support Phase 2 clinical trials in the US and Europe. Vensicas technology offers a minimally invasive alternative to traditional injections, potentially transforming OAB treatment. The partnership with Merz grants Vensica exclusive rights to Xeomin® for needle-less applications in urology, enhancing their clinical development efforts.
InvestmentPartners
growth-positive
Vensica Closes $19 Million Round with Investment from Strategic Partner Merz
Vensica Therapeutics has closed a $19 million investment round, with participation from Merz Group. Vensica is a clinical stage biopharmaceutical company that is developing a needle-free drug delivery platform for urological indications. The funds raised will support the companys phase II clinical trials in Europe and the USA. Vensica is also expanding its workforce in Israel for the next stage of clinical and regulatory development. The investment from Merz Group reflects their commitment to establishing a urology treatment platform and their strategic partnership with Vensica. The article highlights the potential of Vensicas needle-free platform to improve the patient experience and enable more efficacious treatment. The companys CEO and the CEO of Merz Therapeutics both express optimism about the collaboration and the development of less invasive treatments for bladder diseases.
InvestmentPartners
growth-positive
Vensica Therapeutics Closes $16 Million Investment Round
Vensica Therapeutics, a clinical stage biopharmaceutical company, has closed an investment round of $16 million. The investment round was led by Israel Biotech Fund (IBF) and included other investors such as Laborie, Lew Pell, Agriline, and The Trendlines Group. The funds raised will support the companys phase II multicenter clinical trials in Europe and the USA. Vensica Therapeutics has also signed a strategic license and collaboration agreement with Merz Therapeutics, licensing Merzs botulinum neurotoxin A (XEOMIN®) for needle-free use in urological procedures. The company plans to expand its workforce in Israel for the next stage of clinical and regulatory development. Vensicas needle-free platform for drug delivery aims to provide a less invasive and more effective treatment for bladder diseases, including overactive bladder.
Investment
Merz and Israeli Start-Up Vensica Launch Partnership for Needleless Treatment of Overactive Bladder
growth-positive
Cogentix Medical Makes $2 Million Investment in Israeli Company Developing Innovative and Novel Device for Delivery of Drugs to the Bladder
Cogentix Medical has announced a $2 million investment in Vensica Medical, an Israeli-based company developing an ultrasound-based, needle-free drug delivery system called VensiCare. The initial indication for VensiCare will be the delivery of botulinum toxin to treat overactive bladder. Cogentix will receive one seat on the Vensica Board and options to acquire the entire company for an additional $8 million. Cogentix sees the potential of VensiCare to revolutionize the administration of botulinum toxin for overactive bladder and believes it could be a broad-based drug delivery platform for other indications, such as cancer. This investment is part of Cogentixs strategy to prudently invest its cash in a variety of transactions, including acquisition, licensing, and development agreements.
Investment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $33.2M |
| Last funding | $11M |
| Stage | Seed |
| Rounds | 6 |
| Investors | 9 |
Team Members
2
Employees: 11-50
Web & Social Links
| Website | vensica.com |
Locations
HaGavish Street 4, Netanya, Israel
New York, NY, USA
Photos & Videos
1 item(s)
